Regarding mTOR and FASN inhibition in vivo, EGCG (30 mg/kg for 3d/w) reduced tumor growth in the HER2-PDX model after 21 days of treatment (Fig 5A, left panel). This evidence concerns the gene MTOR and neoplasm.